Taysha Gene Therapies, Inc.
Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update
REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA…